Ticker > Company >

Coral Laboratories share price

Coral Laboratories Ltd.

  18.19 K   34   1 BSE: 524506 SECTOR: Pharmaceuticals & Drugs

534.80
+34.65 (6.93%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 544

Today's Low

₹ 501

52 Week High

₹ 679

52 Week Low

₹ 360

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 191.06 Cr.

Enterprise Value

₹ 122.85 Cr.

No. of Shares

0.36 Cr.

P/E

9.95

P/B

0.89

Face Value

₹ 10

Div. Yield

0.37 %

Book Value (TTM)

₹  600.41

CASH

₹ 72.54 Cr.

DEBT

₹ 4.33 Cr.

Promoter Holding

71.51 %

EPS (TTM)

₹  53.76

Sales Growth

-25.31%

ROE

7.98 %

ROCE

11.14%

Profit Growth

-32.18 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-25.31%
3 Year3.22%
5 Year-2.31%

Profit Growth

1 Year-32.18%
3 Year36.47%
5 Year3.86%

ROE%

1 Year7.98%
3 Year10.08%
5 Year8.11%

ROCE %

1 Year11.14%
3 Year13.55%
5 Year10.79%

Debt/Equity

0.0207

Price to Cash Flow

12.24

Interest Cover Ratio

135.8594

CFO/PAT (5 Yr. Avg.)

0.385386468384923

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2026 71.51 0.00
Jun 2026 71.51 0.00
Mar 2026 71.51 0.00
Dec 2025 71.51 0.00
Sep 2025 71.51 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 36.4686293699269% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 135.8594.
  • The company has an efficient Cash Conversion Cycle of 51.7337 days.
  • Company has a healthy liquidity position with current ratio of 6.4801.
  • The company has a high promoter holding of 71.51%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 7.55854572312681.

 Limitations

  • The company has shown a poor revenue growth of 3.21570414951635% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 18.82 19.04 21.56 26.48 29.62
Total Expenditure 16.64 14.1 19.67 20.28 24.14
Operating Profit 2.18 4.94 1.89 6.2 5.49
Other Income 2.05 2.71 2.49 2.65 2.15
Interest 0.06 0.1 0 0.01 0.03
Depreciation 0.45 0.45 0.69 0.54 0.66
Exceptional Items 0 0.32 0 -0.01 0
Profit Before Tax 3.72 7.42 3.7 8.29 6.94
Tax 1.16 1.6 0.92 3.06 1.56
Profit After Tax 2.57 5.82 2.78 5.22 5.39
Adjusted EPS (Rs) 7.18 16.29 7.77 14.62 15.08

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 75.61 78.12 83.66 115.01 85.9
Total Expenditure 67.4 74.31 67.42 88.77 70.69
Operating Profit 8.21 3.81 16.24 26.24 15.21
Other Income 4.81 6.9 6.63 9.11 9.9
Interest 0.14 0.34 0 0.1 0.17
Depreciation 1.99 2.18 1.98 2.01 2.14
Exceptional Items 0.96 0.04 -0.16 -0.77 0.31
Profit Before Tax 11.86 8.23 20.73 32.47 23.11
Tax 2.81 1.78 4.94 8.31 6.73
Net Profit 9.05 6.45 15.79 24.16 16.38
Adjusted EPS (Rs.) 25.32 18.04 44.19 67.61 45.85

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 3.57 3.57 3.57 3.57 3.57
Total Reserves 152.48 151.23 173.92 197.63 205.54
Borrowings 0 0 0 0 0
Other N/C liabilities 8.33 7.69 3.28 3.3 4.24
Current liabilities 25.52 11.86 24.9 24.96 27.31
Total Liabilities 189.9 174.35 205.68 229.46 240.66
Assets
Net Block 22.79 24.3 23.34 21.81 43.23
Capital WIP 1.72 0 0 2.48 0.04
Intangible WIP 0 0 0 0 0
Investments 24.43 17.41 24.04 24.8 16.79
Loans & Advances 9.17 8.13 3.51 2.9 2.74
Other N/C Assets 0.99 0.96 0.94 0.92 0.9
Current Assets 130.8 123.54 153.85 176.55 176.97
Total Assets 189.9 174.35 205.68 229.46 240.66
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 10.9 8.19 20.9 33.24 22.8
Adjustment -0.01 0.38 -1.97 -3.01 -2.78
Changes in Assets & Liabilities -0.44 6.06 -19.51 -24.12 2.71
Tax Paid -4.37 -1.97 -4.88 -7.33 -7.12
Operating Cash Flow 6.08 12.67 -5.46 -1.22 15.62
Investing Cash Flow -6.05 -2.61 1.4 -0.15 -17.71
Financing Cash Flow 0.15 -6.43 0.01 2.71 0.06
Net Cash Flow 0.18 3.62 -4.06 1.33 -2.03

Corporate Actions

Investors Details

PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
promoters 71.51 71.51 71.51 71.51 71.51
chetan navinchandra doshi... 51.54 51.54 51.54 51.54 51.54
coral india finance and h... - - - 19.97 19.97
coral india finance and h... 19.97 19.97 19.97 - -
PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
investors 28.49 28.49 28.49 28.49 28.49
investor education and pr... - - - 2.64 2.63
llp 0.03 0.03 0.02 0.04 0.02
meeta samir sheth 1.84 1.84 1.84 1.84 1.84
neelam mittal - - 1.14 - 1.14
noetic finance private li... 1.05 1.05 1.05 1.06 1.06
pooja bhagwandas - - 1.83 1.83 1.83
neelam mital - - - 1.14 -
iepf 2.49 2.64 2.64 - -
pooja bhagwandas 1.69 1.81 - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Coral Laboratories submits board meeting intimation 21 Sep, 4:02 PM Coral Laboratories informs about newspaper publications 23 Jun, 11:52 AM Coral Laboratories informs about outcome of board meeting 18 Jun, 4:57 PM Coral Laboratories informs about secretarial compliance report 30 May, 3:22 PM Coral Laboratories informs about compliance report 30 May, 2:56 PM Coral Laboratories informs about receipt of notice 27 Apr, 2:54 PM Coral Laboratories - Quaterly Results 14 Feb, 12:00 AM Coral Laboratories - Quaterly Results 13 Aug, 5:40 PM Coral Laboratories - Quaterly Results 13 Aug, 5:40 PM Coral Laboratories informs about closure of trading window 27 Jun, 12:56 PM Coral Laboratories - Quaterly Results 13 Feb, 6:55 PM Coral Laboratories informs about issuance of duplicate share certificate 31 Dec, 5:20 PM Coral Laboratories informs about newspaper publication 4 Sep, 5:05 PM Coral Laboratories - Quaterly Results 14 Aug, 4:43 PM Coral Laboratories - Quaterly Results 14 Aug, 4:43 PM Coral Laboratories informs about appointment of company secretary 13 Jul, 3:57 PM Coral Laboratories informs about resignation of CS cum CO 4 Jul, 5:11 PM Coral Laboratories - Quaterly Results 23 May, 2:56 PM Coral Laboratories - Quaterly Results 23 May, 2:56 PM Coral Laboratories - Quaterly Results 23 May, 2:56 PM Coral Laboratories informs about outcome of board meeting 8 Mar, 12:47 PM Coral Laboratories informs about outcome of board meeting 8 Mar, 12:37 PM Coral Laboratories - Quaterly Results 14 Feb, 2:20 PM Coral Laboratories - Quaterly Results 14 Feb, 2:20 PM Coral Laboratories informs about certificate 15 Jan, 5:00 PM Coral Laboratories informs about details of loss of certificate 16 Oct, 5:01 PM Coral Laboratories - Quaterly Results 12 Aug, 12:44 PM Coral Laboratories informs about loss of share certificate 7 Aug, 2:27 PM Coral Laboratories informs about press release 19 Jul, 3:02 PM Coral Laboratories informs about details of loss of certificate 15 Jul, 3:43 PM Coral Laboratories informs about AGM 11 Jul, 4:49 PM Coral Laboratories informs about loss of share certificate 1 Jun, 12:57 PM Coral Laboratories - Quaterly Results 23 May, 3:32 PM Coral Laboratories - Quaterly Results 23 May, 3:32 PM Coral Laboratories - Quaterly Results 23 May, 3:32 PM Coral Laboratories - Quaterly Results 14 Feb, 3:30 PM Coral Laboratories - Quaterly Results 11 Feb, 3:17 PM Coral Laboratories informs about outcome of board meeting 27 Sep, 3:55 PM Coral Laboratories informs about proceeding of 39th AGM 24 Sep, 2:09 PM Coral Laboratories informs about certificate 9 Jul, 11:55 AM Coral Laboratories informs about outcome of board meeting 27 May, 4:33 PM Coral Laboratories informs about newspaper publication 5 Nov, 3:07 PM Coral Laboratories informs about certificate 8 Oct, 3:07 PM Coral Laboratories informs about clarification on price movements 16 Apr, 10:44 AM

Coral Laboratories Stock Price Analysis and Quick Research Report. Is Coral Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Coral Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Coral Laboratories has a PE ratio of 9.31561481569666 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Coral Laboratories has ROA of 6.9689% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Coral Laboratories has a Current ratio of 6.4801.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Coral Laboratories has a ROE of 7.9846%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Coral Laboratories has a Debt to Equity ratio of 0.0207 which means that the company has low proportion of debt in its capital.

  • Sales growth: Coral Laboratories has reported revenue growth of -25.3081% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Coral Laboratories for the current financial year is 17.7105391520576%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Coral Laboratories is Rs 2 and the yield is 0.4016%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Coral Laboratories is Rs 53.7592. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Coral Laboratories in Ticker for free. Also, one can get the intrinsic value of Coral Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Coral Laboratories FAQs

Q1. What is Coral Laboratories share price today?
Ans: The current share price of Coral Laboratories is Rs 500.8.

Q2. What is the market capitalisation of Coral Laboratories?
Ans: Coral Laboratories has a market capitalisation of Rs 178.915808 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Coral Laboratories?
Ans: The PE ratio of Coral Laboratories is 9.31561481569666 and the P/B ratio of Coral Laboratories is 0.834097811958911, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Coral Laboratories share?
Ans: The 52-week high share price of Coral Laboratories is Rs 679, and the 52-week low share price of Coral Laboratories is Rs 360.

Q5. Does Coral Laboratories pay dividends?
Ans: Currently, Coral Laboratories pays dividends. Dividend yield of Coral Laboratories is around 0.4016%.

Q6. What are the face value and book value of Coral Laboratories shares?
Ans: The face value of Coral Laboratories shares is Rs 10, while the book value per share of Coral Laboratories is around Rs 600.4092. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Coral Laboratories?
Ans: Coral Laboratories has a total debt of Rs 4.3268 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Coral Laboratories?
Ans: The ROE of Coral Laboratories is 7.9846% and ROCE of Coral Laboratories is 11.1363%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Coral Laboratories a good buy for the long term?
Ans: The Coral Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Coral Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Coral Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Coral Laboratories’s financials?
Ans: You can review Coral Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Coral Laboratories
X